Back to Search
Start Over
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
- Source :
-
Blood [Blood] 2022 Jan 27; Vol. 139 (4), pp. 624-629. - Publication Year :
- 2022
- Subjects :
- Adult
Aged
Aged, 80 and over
Blood Platelets cytology
Female
Humans
Leukocyte Count
Male
Middle Aged
Neutrophils cytology
Platelet Count
Activin Receptors, Type II therapeutic use
Blood Platelets drug effects
Hematinics therapeutic use
Immunoglobulin Fc Fragments therapeutic use
Myelodysplastic Syndromes drug therapy
Neutrophils drug effects
Recombinant Fusion Proteins therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 139
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Report
- Accession number :
- 34758066
- Full Text :
- https://doi.org/10.1182/blood.2021012589